(Yicai Global) Sept. 6 -- China National Biotec Group, a unit of Chinese drugmaker Sinopharm, has received the approval from the country’s regulator to begin clinical trials of the world’s first human immunoglobulin (pH4) intravenous injection against Covid-19.
The specific immunoglobulin used in the drug is made from healthy human plasma containing Covid-19 antibodies and high-potency SARS-CoV-2 neutralizing antibodies, Sinopharm announced on its official WeChat account on Sept. 3. No other pharmaceutical companies had applied for clinical trials of such drug.
The injection has also received clinical trial approval from the United Arab Emirates' health regulator, the firm added.
Sinopharm’s stock price [HKG:1099] closed up 2.7 percent today at HKD21.20 (USD2.71).
CNBG's first inactivated Covid-19 vaccine was approved for conditional sale in China at the end of last year, becoming the first of its kind in the county. It was also certified for emergency use by the World Health Organization on May 7.
Two inactivated Covid-19 vaccines from Sinopharm's unit have been approved for conditional sale in China, with other two adopting different approaches still in clinical trials.
Editor: Futura Costaglione